EVOK
- Evoke Pharma, Inc.
()
Overview
Company Summary
Evoke Pharma, Inc. is a pharmaceutical company focused on the development and commercialization of drug products for the treatment of gastrointestinal (GI) disorders. The company is primarily engaged in developing novel products for disorders that affect the upper GI tract.
One of Evoke Pharma's main areas of focus is developing therapies for patients suffering from diabetic gastroparesis. Gastroparesis is a condition in which the stomach muscles do not function properly, leading to delayed gastric emptying. This can cause symptoms such as nausea, vomiting, and abdominal pain. Evoke Pharma has developed a product called Gimoti (metoclopramide) nasal spray, which aims to provide relief for adults with acute and recurrent diabetic gastroparesis. Gimoti is intended to accelerate gastric emptying and improve symptoms.
Evoke Pharma's primary product, Gimoti, is a unique formulation of the drug metoclopramide delivered through nasal sprays. The nasal spray delivery method allows for more rapid absorption and onset of action compared to traditional oral administration. This potential advantage could be especially beneficial for patients who have difficulty swallowing or who experience nausea and vomiting, as it bypasses the GI tract.
In addition to developing Gimoti, Evoke Pharma is involved in the development of other potential therapies for GI disorders and has a focus on utilizing innovative drug delivery methods to provide effective treatments.
Overall, Evoke Pharma, Inc. is dedicated to addressing the unmet needs of patients with GI disorders, particularly diabetic gastroparesis, through the development and commercialization of novel and convenient drug products.